Advancing Therapy for IBD Through Novel Mechanisms and Emerging Agents: A Rapid-Fire Roundtable Discussion

1.25 AANP
1.25 CME
$0 FEE


Provider Statement

This continuing medical education activity is provided by the .

In partnership with Vindico Medical Education.

Support Statement

This activity is supported by educational grants from Celgene Corporation and Genentech, Inc.

Activity Description

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is a chronic, frequently progressive condition that affects approximately 3 million people in the United States. IBD is associated with significant morbidity, diminished quality of life, and, in some cases, mortality. To meet the persistent challenges associated with managing patients with moderate to severe IBD, health care professionals must be knowledgeable regarding the wide variety of existing and emerging agents to treat these diseases. Ongoing education is required to remain current regarding the evidence-based and expert-recommended strategies for managing IBD. In this recorded CME symposium, expert faculty describe the pathogenesis of IBD and the mechanisms of action of existing and novel therapies as well as assessing the clinical evidence to support the safety and efficacy of emerging agents for treating patients with IBD. This activity features Rapid-Fire Roundtable, an engaging, fast-paced exchange of clinical expert perspectives to promote enhanced learning.

Target Audience

The intended audience for this activity is gastroenterologists, internists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Describe the known pathways and mechanisms that contribute to the pathogenesis of Crohn’s disease and ulcerative colitis.
  • Compare the mechanisms of action of currently available agents versus novel emerging agents for the management of moderate to severe IBD.
  • Assess the clinical evidence regarding the safety and efficacy of emerging agents for the treatment of IBD.

Activity Chair

David T. Rubin, MD, AGAF
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL


Britt Christensen, BSc, MBBS (Hons), MPH
Head of Inflammatory Bowel Disease
Gastroenterology Department
The Royal Melbourne Hospital
Melbourne, Australia

Millie D. Long, MD, MPH
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
University of North Carolina at Chapel Hill
Division of Gastroenterology and Hepatology
Chapel Hill, NC

Alan C. Moss, MD, AGAF
Director, Crohn's & Colitis Program
Boston Medical Center
Boston University
Boston, MA


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Linda A. Giarraputo PA-C


The American Gastroenterological Association is accredited by the Accreditation of Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The American Gastroenterological Association designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is approved for 1.25 contact hour(s) of continuing education (which includes 1.25 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20024182.

This activity was planned in accordance with AANP Accreditation Standards and Policies.


This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid for one year from 3/31/2020. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of the post-test is required to earn AAPA Category 1 CME credit. Successful completion is defined as a cumulative score of at least 70 percent correct.

This enduring material is approved for 1 year from the date of original release, March 31, 2020, to March 30, 2021.

How to Participate in This Activity and Obtain CE Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the content, and complete the CE posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, the American Gastroenterological Association will issue an AMA PRA Category 1 Credit(s)™ Certificate or Vindico Medical Education will issue an AANP Contact Hours certificate or an AAPA Category 1 CME Certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Activity Chair and Faculty report the following relationship(s)

Britt Christensen, BSc, MBBS (Hons), MPH
Consulting Fee: Gilead, Novartis
Speakers Bureau: AbbVie, Janssen, Pfizer, Takeda

Millie D. Long, MD, MPH
Consulting Fee: AbbVie, Janssen, Pfizer, Prometheus, Salix, Takeda, Target PharmaSolutions, UCB, Valeant

Alan C. Moss, MD, AGAF
Consulting Fee: Janssen, Pfizer

David T. Rubin, MD, AGAF
Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene/Syneos, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Ichnos Sciences, Janssen, Lilly, Mahana Therapeutics, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions, Techlab, Inc.
Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
Ownership Interest: AbGenomics, Biomica
Board of Trustees: American College of Gastroenterology
Co-Founder: Cornerstone Health, Inc., GoDuRun, LLC

Reviewers report the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Linda A. Giarraputo PA-C
No relevant financial relationships to disclose.

The American Gastroenterological Association and Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at the American Gastroenterological Association and Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and the American Gastroenterological Association continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and the American Gastroenterological Association. Neither Vindico Medical Education, The American Gastroenterological Association, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at